NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)
|
|
|
- Hubert Merritt
- 6 years ago
- Views:
Transcription
1 HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir HIV 17 Dec 2010 Actelion Pharmaceuticals Canada Inc. Toctino 10 mg/capsule alitretinoin Eczema 11 Jan 2011 Alcon Canada Inc. Pataday 2 mg/ml olopatadine hydrochloride Allergies 14 Apr 2011 STATUS Does Not Trigger Does Not Trigger Allergan Inc. Ozurdex 0.7 mg/implant dexamethasone Macular Edema 3 Jun 2011 Amgen Canada Inc. Vectibix 20 mg/ml panitumumab Colorectal Cancer May 2008 (patented 30 Aug 2011) Xgeva 120 mg/vial denosumab Bone Metabolism Regulator 18 May 2011 Brilinta 90 mg/tablet ticagrelor Heart 8 Jun 2011 AstraZeneca Canada Inc. Vimovo 20/ mg/tablet esomeprazole magnesium/naproxen Osteoarthritis 4 Feb 2011 Vimovo 20/ mg/tablet Baxter Corporation Feiba NF 2500 factor viii anti inhibitor Haemophilia 4 Apr 2011 Tisseel VHSD Kit 500 unit/ml fibrin sealant Wound Healing 31 May 2011 Bayer Inc. Staxyn 10 mg/tablet vardenafil hydrochloride Erectile Dysfunction 25 Aug 2011 Trajenta 5 mg/tablet linagliptin Diabetes 13 Sep 2011 Boehringer Ingelheim (Canada) Ltd. Twynsta 40/5 45 mg/tablet telmisartan/amlodipine besylate Aug 2011 Twynsta 40/10 50 mg/tablet telmisartan/amlodipine besylate Hypertension 11 Aug 2011 Twynsta 80/5 85 mg/tablet telmisartan/amlodipine besylate Aug 2011 PMPRB 1
2 Twynsta 80/10 90 mg/tablet telmisartan/amlodipine besylate Aug 2011 Viramune XR 400 mg/tablet nevirapine HIV 27 Sep 2011 Bristol-Myers Squibb Canada Co. Sprycel 140 mg/tablet dasatinib Leukemia 30 Mar 2011 Celgene Corporation Thalomid 100 mg/capsule thalidomide Multiple myeloma 17 Feb 2011 Thalomid 200 mg/capsule Banzel 100 mg/tablet Oct 2011 Eisai Limited Banzel 200 mg/tablet rufinamide Epilepsy 30 Aug 2011 Banzel 400 mg/tablet Aug 2011 Halaven 0.5 mg/ml eribulin mesylate Breast Cancer 29 Jun 2011 Eli Lilly Canada Inc. Byetta 5 mcg/dose exenatide Diabetes 1 Jun 2011 Byetta 10 mcg/dose exenatide Diabetes 31 May 2011 EMD Serono Canada Inc. Luveris 75 mg/vial lutropin alpha Fertility Galderma Canada Inc. Tactuo 1/25 26 mg/gm adapalene/benzoyl peroxide Acne 28 Jun 2005 (patented 8 Nov 2011) 3 May 2011 (patented 8 Nov 2011) Genzyme Canada Inc. Mozobil 20 mg/ml plerixafor Stem cell mobilization 8 Feb 2011 Renvela 800 mg/tablet sevelamar carbonate Kidneys 27 May 2011 Gilead Sciences Inc. Complera 200/300/ mg/tablet emtricitabine/tenofovir disodium fumarate/rilpivirine HCL HIV 20 Oct 2011 Glaxosmithkline Inc. Benlysta 120 mg/vial belimumab Lupus 25 Aug 2011 PMPRB 2
3 Benlysta 400 mg/vial Jalyn 0.5/ mg/capsule dutasteride/tamsulosin hydrochloride Benign prostatic hyperplasia 15 Nov 2011 Revolade 25 mg/tablet eltrombopag olamine Bleeding 1 Apr 2011 Revolade 50 mg/tablet Verdeso 0.5 mg/gm desonide Eczema 20 Apr 2011 Votrient 200 mg/tablet pazopanib hydrochloride Renal Cancer 17 Aug 2010 (patented 15 Mar 2011) Hospira Healthcare Corporation (Canada) Docetaxel 10 mg/ml docetaxel Various Cancers 1 Mar 2011 Edurant 25 mg/tablet rilpivirine hydrochloride HIV 6 Sep 2011 Nucynta CR 50 mg/tablet Nucynta CR 100 mg/tablet Janssen Inc. Nucynta CR 150 mg/tablet tapentadol hydrochloride Pain 14 Mar 2011 Nucynta CR 200 mg/tablet Nucynta CR 250 mg/tablet Zytiga 250 mg/tablet abiraterone acetate Prostate Cancer 18 Aug 2011 Johnson & Johnson Medical Products Evicel thrombin (human)/fibrinogen (human) Haemorrhage During Surgery 3 Mar 2011 Labopharm Inc. Oleptro 150 mg/caplet trazadone hydrochloride Antidepressant 9 Mar 2011 Oleptro 300 mg/caplet PMPRB 3
4 Onsolis 200 mcg/film NEW PATENTED MEDICINES REPORTED TO PMPRB Onsolis 400 mcg/film Meda Valeant Pharma Canada Inc. Onsolis 600 mcg/film fentanyl citrate Pain 22 Aug 2011 Onsolis 800 mcg/film Onsolis 1200 mcg/film Emend IV 150 mg/vial fosaprepitant dimeglumine Nausea and vomiting 4 Apr 2011 Victrelis Triple 200/200/ Aug 2011 Merck Canada Inc. Victrelis Triple 200/200/100 Victrelis Triple 200/200/120 Victrelis Triple 200/200/ Aug 2011 Hepatitis C Aug Aug 2011 Zenhale 50/5 55 mcg/dose mometasone furoate/formoterol fumarate Asthma 20 Jun 2011 Zenhale 100/5 105 mcg/dose mometasone furoate/formoterol fumarate Asthma 10 Mar 2011 Zenhale 200/5 205 mcg/dose mometasone furoate/formoterol fumarate Asthma 17 Jun 2011 Novartis Pharma Canada Inc. Afinitor 2.5 mg/tablet everolimus Renal cancer 5 Aug 2011 Afinitor 5 mg/tablet Feb 2011 Gilenya 0.5 mg/capsule fingolimod hydrochloride Multiple sclerosis 28 Mar 2011 Ilaris 150 mg/vial canakinumab Cryopyrin associated periodic syndromes 27 Apr 2010 (patented 26 Apr 2011) PMPRB 4
5 meningococcal (Groups A, C, W-135 Menveo 63.8 mcg/dose and Y) oligosaccharide CRM Vaccine conjugate 3 Aug 2010 (patented 8 Feb 2011) Tasigna 150 mg/capsule Nilotinib Leukemia 15 Jul 2011 Tobi Podhaler 28 mg/capsule tobramycin Cystic Fibrosis 12 May 2011 Nycomed Canada Inc. Daxas 500 mcg/tablet roflumilast Chronic Obstructive Pulmonary Disease (COPD) 20 Dec 2010 Abstral 100 mcg/tablet fentanyl citrate Opioid analgesic 26 May 2011 Abstral 200 mcg/tablet fentanyl citrate Opioid analgesic 14 Jun 2011 Paladin Labs Inc. Abstral 300 mcg/tablet fentanyl citrate Opioid analgesic 14 Jun 2011 Abstral 400 mcg/tablet fentanyl citrate Opioid analgesic 14 Jun 2011 Abstral 600 mcg/tablet fentanyl citrate Opioid analgesic 14 Jun 2011 Abstral 800 mcg/tablet fentanyl citrate Opioid analgesic 14 Jun 2011 Pat-Galantamine ER 8 mg/capsule Patriot, A Division of Janssen Inc. Pat-Galantamine ER 16 mg/capsule galantamine hydrobromide Alzheimer disease 11 Jan 2011 Pat-Galantamine ER 24 mg/capsule Oxyneo 10 mg/tablet Purdue Pharma Oxyneo 15 mg/tablet oxycodone hydrochloride Pain 13 Sep 2011 Oxyneo 20 mg/tablet Oxyneo 30 mg/tablet PMPRB 5
6 Oxyneo 40 mg/tablet Oxyneo 60 mg/tablet Oxyneo 80 mg/tablet Zytram XL 75 mg/tablet tramadol hydrochloride Zytram XL 100 mg/tablet Pain 2 Mar 2011 Sanofi-Aventis Canada Inc. Jevtana 60 mg/vial cabazitaxel Prostate cancer 23 Dec 2010 Sanofi Pasteur Limited Adacel-Polio DTaP-IPV Vaccine 15 Mar 2011 Menactra diphtheria toxoid/meningococcal polysaccharide/conjugate vaccine Vaccine Oct 2006 (patented 21 Jun 2011) Vyvanse 20 mg/capsule Apr 2010 Vyvanse 30 mg/capsule Aug 2009 Shire Canada Inc. Vyvanse 40 mg/capsule lisdexamfetamine dimesylate ADHD Apr 2010 Vyvanse 50 mg/capsule Aug 2009 Vyvanse 60 mg/capsule Apr 2010 Shire Human Genetic Therapies Inc. Firazyr 20 mg/syringe icatibant Heart 2 Feb 2011 Valeant Canada LP Biacna 1.2/0.025 clindamycin phosphate/tretinoin Acne 16 May 2011 Warner Chilcott Canada Co. Actonel DR 35 mg/tablet risedronate sodium Osteoporosis in women 19 Sep 2011 Seasonique.15/.03/.01 levonorgestrel/ethinyl estradiol + ethinyl estradiol Contraceptive 18 Apr 2011 PMPRB 6
7 Watson Pharma Company Rapaflo 4 mg/capsule silodosin Benign prostate hyperplasia 26 Oct 2011 Rapaflo 8 mg/capsule TOTAL: 103 DINs 11(1) 45 DINs 11(2) 58 DINs PMPRB 7
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
Health Newsflash a Quarterly Publication
at the January to March DEC The Drug Evaluation Committee (DEC) of ESI Canada conducts monthly reviews of all new drugs receiving their Notices of Compliance from Health Canada, to ascertain their place
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Novartis Pharmaceuticals Corporation - US Postmarketing Commitments October 2016 (Ongoing)
Novartis Pharmaceuticals Corporation - US Postmarketing Commitments October 2016 () Brand Name Generic Name Application Commitment Number Approval Date Commitment Number/Description Afinitor Everolimus
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
Novartis Pharmaceuticals Corporation - US Postmarketing Commitments Ongoing [October 2018]
![Novartis Pharmaceuticals Corporation - US Postmarketing Commitments Ongoing [October 2018]](/thumbs/90/103470094.jpg "Novartis Pharmaceuticals Corporation - US Postmarketing Commitments Ongoing [October 2018]")
Novartis Pharmaceuticals Corporation - US Postmarketing s [October 2018] /Description Afinitor Everolimus BHT 22334 30-Mar-2009 PMR#3031-1: To submit the clinical study report and datasets for the final
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada,
1 Appendix Commentary 515 Appendix: Assessing Canada s Drug Shortage Problem Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada, 2013 16 Drug Name Dosage Therapeutic
SickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
CONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
INSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
The Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
Health Newsflash a Quarterly Publication
The Drug Evaluation Committee (DEC) of Express Scripts Canada conducts monthly reviews of all new drugs receiving their Notices of Compliance from Health Canada, to ascertain their place in therapy and
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
JABLONSKI DEBATES PSA TESTING
The JABLONSKI DEBATES PSA TESTING Getting Prostrate for the Prostate The JABLONSKI DEBATES Learning has never been this much fun (just like walking through a field littered with land mines.) The JABLONSKI
Lancet 2008; 372 : CDF. N Engl J Med Aug 28;349(9): J Clin Oncol May 15;19(10): Cancer Nov 1;113(9):2471-7
Tumour Group: UROLOGY Renal Palliative Sunitinib 1 st line therapy Lancet. 1999 Jan 2;353(9146):14-7. Pazopanib 1 st line therapy J Clin Oncol. 2010 28(06):1061-1068 Everolimus 2 nd or 3 rd line in adv./metas.rcc
FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE INTRODUCTION This Data Digest reports on changes in manufacturer prescription drug prices
Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Critical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
ENROLLMENT : Line of Business Summary
ENROLLMENT : Line of Business Summary Date Range : JAN 2017 through DEC 2017 COMPREHENSIVE MAJOR MEDICAL Print Date : 1/19/2018 9:43:49AM Page 1 of 1 Month Year Single 2 Person : Emp/Spouse 2 Person :
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
ACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNCA.01 Effective Date: 11.16.16 Last Review Date: 04.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 47/26/0920 SANOFI-AVENTIS
Jan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X
Primary Prevention Breast Cancer Prevention Member: Mammography reminder letters to female members ages 51.5-74 who are overdue to get a mammogram Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Providers:
Equianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
CIALIS (See-AL-iss) (tadalafil) tablets
1 Patient Information CIALIS (See-AL-iss) (tadalafil) tablets Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find
NICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
Poisoning Death Review Report. Montgomery County, 2017
Poisoning Death Review Report Public Health Dayton & Montgomery County Prepared by Epidemiology Section Published May 15, 2018 Page 2 of 53 Contents Executive Summary... 5 Number of Drug Overdose... 5
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
Radium-223 and Targeted Alpha Therapy Thinking About Tomorrow
Radium-223 and Targeted Alpha Therapy Thinking About Tomorrow Oliver Sartor, M.D. Laborde Professor for Cancer Research Medical Director, Tulane Cancer Center Assistant Dean for Oncology Tulane Medical
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA JULY 2013 PBAC MEETING. Closing date for consumer comments 12 June 2013
The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the PBS or the National Immunisation Program. The PBAC agenda consists of the following: 1 Minutes
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
Back in a few minutes Geoff
Back in a few minutes Geoff Conflict of Interest Speaker Name; Dr. Geoff Davis Program Title FINANCIAL DISCLOSURE Grants/Research Support: Archimedes Research Speakers Bureau/Honoraria:Purdue Pharma, Pfizer
Pharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
Oncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
Morphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
Kansas EMS Naloxone (Narcan) Administration
Kansas EMS Naloxone (Narcan) Administration Executive Summary Kansas Board of Emergency Medical Services August 217 The following pages denote an ongoing trending of naloxone administration by Kansas Emergency
STEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
Table of Contents. Introduction and Summary. KEI Research Note 2011:1 August 4, 2011 Paul Miano
Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines KEI Research
Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
Pharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Age Edits Rx.01.2 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications
Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
25 June 2010 corr. 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2010 Positive opinions for new medicines adopted The Committee
US Postmarketing Study Commitments (Updated June 2016) Compound Name
Compound US Postmarketing Study s (Updated June 2016) Compound Arimidex Description of NDA Number Date Given Description of NDA Number Although not required to obtain pediatric exclusivity, we request
Major Health Awareness Days in 2016
Major Health Awareness Days in 2016 Whole year International Year of Pulses January All summer Big Red BBQ (Kidney Foundation) National Cervical Health Awareness Month February Ovarian Cancer Awareness
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
2018 Health Awareness Calendar
2018 Health Awareness Calendar January SunSmart Skin Cancer Awareness Month (1 December to 31 January) 04 World Braille Day 28 World Leprosy Day February Healthy Lifestyle Awareness Month Reproductive
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
This article is a CME/CE certified activity. To earn credit for this activity visit:
Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies
Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Health Calendar. January. February Souvenir TFW Pen Pocket Slider: Safe Dating
2019 Health Calendar January Blood Donor Month Cervical Health Awareness Month National Birth Defects Prevention Month National Glaucoma Awareness Month National Radon Action Month National Stalking Awareness
PRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
Creighton University Internal Medicine Residency Curriculum Cycle of 33 months
Creighton University Internal Medicine Residency Curriculum Cycle of 33 months Cardiology: 13 lectures and once a month EKG lecture, 25 total 1. EKG interpretation Once a month 2. Heart failure: 2 lectures.
Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
Men s Health Ted Jablonski MD CCFP FCFP. ASA Banff March Associate, Crowfoot Village Family Practice, Calgary AB
Men s Health 2018 UP date on DOWN below Dr Ted Jablonski MD CCFP FCFP ASA Banff March 2018. Ted Jablonski MD CCFP FCFP Associate, Crowfoot Village Family Practice, Calgary AB Medical Lead Calgary Foothills
Executive Summary. Reproduction prohibited v
Kinases are a large family of proteins that have now become firmly established as a major class of drug targets for the pharmaceutical industry. The sequencing of the Human Genome has led to the identification
Peking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
A Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
An Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits
NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits Overall Goal: To identify strategies for providing comprehensive care during a well visit. The provision of comprehensive
Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
Seasonality of influenza activity in Hong Kong and its association with meteorological variations
Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific
PATIENT MEDICATION INFORMATION. MEGACE OS Megestrol acetate Oral Suspension
PATIENT MEDICATION INFORMATION MEGACE OS Megestrol acetate Oral Suspension Read this carefully before you start taking MEGACE OS and each time you get a refill. This leaflet is a summary and will not tell
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
Novartis Pharmaceuticals Corporation - US Postmarketing Commitments October 2016 (Fulfilled)
Novartis Pharmaceuticals Corporation - US Postmarketing Commitments October 2016 () Brand Name Generic Name Application Commitment Date Description of Postmarketing PMC identifier Number (Approval Date)
One Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube
Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube On Aug. 24, 2015, Allergan recalled three lots (86258 expires September 2017, 87189 December 2017 and 87514 February
Medicare Part D 2012 Formulary Changes Service To Senior and Total Fit
Medicare Part D 2012 Formulary s Service To Senior and Total Fit Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday 8 th May 2012. Classification of products: R = RED
July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend. Drug Type and Use. Drug Name, form(s), strength(s), Sponsor,
July 2014 PBAC OUTCOMES - "1 st time" decisions not to recommend Drug Name, form(s), ABIRATERONE, tablet, 250 mg, Zytiga Janssen-Cilag Pty Ltd Change to listing Prostate Cancer Section 85 Authority required
Sickle Cell Anaemia. ADNM Drug Originator Originator Now Co. Code MoA MoA Code Molecular formula CompoundType Route Dec_01 Jun_02 Dec_02
ADNM Originator Originator Now Co. Code MoA MoA Code Molecular formula CompoundType Route Dec_01 Jun_02 Dec_02 Nonindustrial Bar-Ilan University AI Fetal haemoglobin stimulants Angiogenix Inc Angiogenix
2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
Pfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
NAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian